The clinical spectrum of multiple endocrine neoplasia type 2a caused by the rare intracellular RET mutation S891A

Journal of Clinical Endocrinology and Metabolism

Volumn 95, Issue 9, 2010, Pages

  Schulte, Klaus Martin ^a   Machens, Andreas ^a   Fugazzola, Laura ^c   McGregor, Alan ^d   Diaz Cano, Salvador ^a   Izatt, Louise ^b   Aylwin, Simon ^a   Talat, Nadia ^a   Beck Peccoz, Paolo ^c   Dralle, Henning ^d  

^a KING S COLLEGE HOSPITAL   (United Kingdom)

^b KING'S COLLEGE LONDON   (United Kingdom)

^c UNIVERSITY OF MILAN   (Italy)

^d MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN RET; ALANINE; RET PROTEIN, HUMAN; SERINE;

ADOLESCENT; ADULT; AGED; ARTICLE; CLINICAL FEATURE; CORNEA THICKNESS; FEMALE; FOLLOW UP; GENE MUTATION; HETEROZYGOTE; HUMAN; MAJOR CLINICAL STUDY; MALE; ONSET AGE; PARATHYROID HYPERPLASIA; PHEOCHROMOCYTOMA; PRIORITY JOURNAL; SIPPLE SYNDROME; THYROID MEDULLARY CARCINOMA; ADRENAL GLAND NEOPLASMS; AMINO ACID SUBSTITUTION; CARCINOMA, MEDULLARY; CLINICAL TRIAL; COMPLICATION; GENE FREQUENCY; GENETIC ASSOCIATION; GENETICS; MIDDLE AGED; MULTICENTER STUDY; MULTIPLE ENDOCRINE NEOPLASIA TYPE 2A; PHENOTYPE; PHYSIOLOGY; POINT MUTATION; THYROID TUMOR; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADRENAL GLAND NEOPLASMS; ADULT; AGED; AGED, 80 AND OVER; ALANINE; AMINO ACID SUBSTITUTION; CARCINOMA, MEDULLARY; GENE FREQUENCY; GENETIC ASSOCIATION STUDIES; HUMANS; MIDDLE AGED; MULTIPLE ENDOCRINE NEOPLASIA TYPE 2A; PHENOTYPE; PHEOCHROMOCYTOMA; POINT MUTATION; PROTO-ONCOGENE PROTEINS C-RET; SERINE; THYROID NEOPLASMS; YOUNG ADULT;

EID: 77956571207     PISSN: 0021972X     EISSN: 0021972X     Source Type: Journal    
DOI: 10.1210/jc.2010-0375     Document Type: Article

References (19)

1. Eng C, Smith DP, Mulligan LM, Nagai MA, Healey CS, Ponder MA, Gardner E, Scheumann GF, Jackson CE, Tunnacliffe A, et al 1994 Point mutation within the tyrosine kinase domain of the RET protooncogene in multiple endocrine neoplasia type 2B and related sporadic tumours. Hum Mol Genet 3:237-241
2. Machens A, Dralle H 2007 Genotype-phenotype based surgical concept of hereditary medullary thyroid carcinoma. World J Surg 31: 957-968
3. Elisei R, Romei C, Cosci B, Agate L, Bottici V, Molinaro E, Sculli M, Miccoli P, Basolo F, Grasso L, Pacini F, Pinchera A 2007 RET genetic screening in patients with medullary thyroid cancer and their relatives: experience with 807 individuals at one center. J Clin Endocrinol Metab 92:4725-4729
4. Brauer VF, Scholz GH, Neumann S, Lohmann T, Paschke R, Koch CA 2004 RET germline mutation in codon 791 in a family representing 3 generations from age 5 to age 70 years: should thyroidectomy be performed? Endocr Pract 10:5-9
5. Machens A, Dralle H 2008 Familial prevalence and age of RET germline mutations: implications for screening. Clin Endocrinol (Oxf) 69:81-87
6. Machens A, Lorenz K, Dralle H 2009 Constitutive RET tyrosine kinase activation in hereditary medullary thyroid cancer: clinical opportunities. J Intern Med 266:114-125
7. Fugazzola L, Cerutti N, Mannavola D, Ghilardi G, Alberti L, Romoli R, Beck-Peccoz P 2002 Multigenerational familial medullary thyroid cancer (FMTC): evidence for FMTC phenocopies and association with papillary thyroid cancer. Clin Endocrinol (Oxf) 56:53-63
8. Machens A, Lorenz K, Dralle H 2009 Individualization of lymph node dissection in RET (rearranged during transfection) carriers at risk for medullary thyroid cancer: value of pretherapeutic calcitonin levels. Ann Surg 250:305-310
9. Jimenez C, Habra MA, Huang SC, El-Naggar A, Shapiro SE, Evans DB, Cote G, Gagel RF 2004 Pheochromocytoma and medullary thyroid carcinoma: a new genotype-phenotype correlation of the RET protooncogene 891 germline mutation. J Clin Endocrinol Metab 89:4142-4145
10. Hofstra RM, Fattoruso O, Quadro L, Wu Y, Libroia A, Verga U, Colantuoni V, Buys CH 1997 A novel point mutation in the intracellular domain of the ret protooncogene in a family with medullary thyroid carcinoma. J Clin Endocrinol Metab 82:4176-4178
11. Dang GT, Cote GJ, Schultz PN, Khorana S, Decker RA, Gagel RF 1999 A codon 891 exon 15 RET proto-oncogene mutation in familial medullary thyroid carcinoma: a detection strategy. Mol Cell Probes 13:77-79
12. Yip L, Cote GJ, Shapiro SE, Ayers GD, Herzog CE, Sellin RV, Sherman SI, Gagel RF, Lee JE, Evans DB 2003 Multiple endocrine neoplasia type 2: evaluation of the genotype-phenotype relationship. Arch Surg 138:409-416; discussion 416
13. Asari R, Scheuba C, Kaczirek K, Niederle B 2006 Estimated risk of pheochromocytoma recurrence after adrenal-sparing surgery in patients with multiple endocrine neoplasia type 2A. Arch Surg 141: 1199-1205; discussion 1205
14. Wohllk N, Becker P, Youlton R, Cote GJ, Gagel RF 2001 [Germline mutations of the ret proto-oncogene in Chilean patients with hereditary and sporadic medullary thyroid carcinoma]. Rev Med Chil 129:713-718 (Spanish)
15. Paszko Z, Sromek M, Czetwertynska M, Skasko E, Czapczak D, Wisniewska A, Prokurat A, Chrupek M, Jagielska A, Kozlowicz-Gudzinska I 2007 The occurrence and the type of germline mutations in the RET gene in patients with medullary thyroid carcinoma and their unaffected kindred's from Central Poland. Cancer Invest 25:742-749
16. DeLellis RA LR, Heitz PU, Eng C (Eds) 2004 World Health Organization Classification of Tumours. Pathology and genetics of tumours of endocrine organs. Lyon, France: IARC Press
17. Iwashita T, Kato M, Murakami H, Asai N, Ishiguro Y, Ito S, Iwata Y, Kawai K, Asai M, Kurokawa K, Kajita H, Takahashi M 1999 Biological and biochemical properties of Ret with kinase domain mutations identified in multiple endocrine neoplasia type 2B and familial medullary thyroid carcinoma. Oncogene 18:3919-3922
18. Kloos RT, Eng C, Evans DB, Francis GL, Gagel RF, Gharib H, Moley JF, Pacini F, Ringel MD, Schlumberger M, Wells Jr SA 2009 Medullary thyroid cancer: management guidelines of the American Thyroid Association. Thyroid 19:565-612
19. Kim WG, Gong G, Kim EY, Kim TY, Hong SJ, Bae Kim W, Shong YK 2010 Concurrent occurrence of medullary thyroid carcinoma and papillary thyroid carcinoma in the same thyroid should be considered as coincidental. Clin Endocrinol (Oxf) 72:256-263